STSergey Tereshchenko

Sergey Tereshchenko

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sergey Tereshchenko has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Prevention of heart failure — is there a choice?

    by I. V. Zhirov, N. V. Romanova, S. N. Tereshchenko, И. В. Жиров, Н. В. Романова, С. Н. Терещенко

    Effective treatment of arterial hypertension (AH) is important for preventing or delaying the development of chronic heart failure (CHF) and reducing associated hospitalizations and mortality. Despite the proven benefits of AH control, epidemiological data demonstrate that the effectiveness of antihypertensive therapy remains low at the population level. Combination therapy at the start of hypertension treatment is recommended for the majority of patients, and the combination of an angiotensin II receptor blocker and a diuretic is one of the most rational choices. This review systematizes studies on the use of azilsartan medoxomil with chlorthalidone in patients with CHF or at high risk of its development.

  • Non-steroidal mineralocorticoid receptor antagonists in patients with chronic heart failure with reduced left ventricular ejection fraction and chronic kidney disease

    by A.U. Normuradov, I.V. Zhirov, S.N. Tereshchenko

    Despite available treatment methods, combination of chronic heart failure with reduced left ventricular ejection fraction (HFrEF) and chronic kidney disease (CKD) is still associated with an extremely poor prognosis. According to the literature, spironolactone, the first mineralocorticoid receptor antagonist (MRA) recommended for HFrEF, not only fails to improve progression and prognosis of CKD, but also significantly increases the risk of hyperkalemia and mortality. Finerenone was developed as a new-generation MRA with acceptable risk of adverse events comparable to placebo. Large studies demonstrated a significant impact on course and prognosis of CKD in patients with type 2 diabetes mellitus and HF with moderately reduced and preserved left ventricular ejection fraction. However, there are no results from randomized clinical trials regarding combination of HFrEF and CKD. This review examines pathogenesis of chronic heart failure and kidney disease, where mineralocorticoid receptors have a central role. A comparative analysis of steroidal and nonsteroidal MRAs is presented from the perspective of CHF and CKD treatment.

  • Open Access

    Pulmonary embolism, patent foramen ovale, and multiple paradoxical embolism: a case report

    by L. I. Syromyatnikova, A. V. Pavlova, A. A. Kulesh, S. A. Mekhryakov, N. A. Kaileva, O. V. Lapin, A. S. Chubarov, V. V. Likhachev, S. N. Tereshchenko, Л. Н. Сыромятникова, et al.

    This article presents a case of multiple venous thromboembolic events followed by paradoxical embolism in the systemic circulation arteries in a young woman. The factors that contributed to venous thrombosis and pulmonary embolism included long-term use of hormonal contraception, class 1 obesity, initial physical inactivity that peaked after an acute respiratory viral infection, and probable endothelial dysfunction secondary to the viral infection. This case presents the current status of the problem of the combination of paradoxical and pulmonary embolism, patent foramen ovale, and the specifics of managing this patient population.

  • Open Access

    Prevalence, clinical, and prognostic role of metabolic syndrome in patients with heart failure: A subanalysis of the PRIORITY-HF study

    by E. V. Shlyakhto, Yu. N. Belenkov, S. A. Boytsov, S. V. Villevalde, A. S. Galyavich, M. G. Glezer, N. E. Zvartau, Zh. D. Kobalava, Yu. M. Lopatin, V. Yu. Mareev, et al.

    Aim. To assess the prevalence of individual components of metabolic syndrome (MS), the incidence of MS, and its clinical and prognostic significance in outpatients with heart failure (HF). Material and methods. This retrospective analysis of data from the PRIORITY-HF multicenter registry study of patients with HF in the Russian Federation was conducted. The analytical cohort included 19939 patients, and the primary and se­condary criteria of MS were analyzed. A group with MS was identified according to diagnostic criteria, and combinations of components were assessed. In addition, cluster analysis was performed, and prognosis was evaluated. Results. In the analyzed cohort, the primary criteria of MS were identified with high frequency as follows: obesity in 45,6%, HTN in 89%, and type 2 diabetes in 27,4% of patients. Among the additional criteria, the highest prevalence was observed for dyslipidemia/lipid-lowering therapy in 80,7%, impaired renal function/damage in 62%, and hyperuricemia/urate-lowering therapy in only 5% of patients. MS was diagnosed in 14403 (70,4%) patients. Among patients with MS, the following distribution was noted depending on the burden of main criteria: 48,8% — 2, 28% — 1, and 23,2% — 3 main criteria. The most frequent combination was HTN + dyslipidemia/lipid-lowering therapy + impaired renal function/damage both in the overall cohort with MS and in the subgroups by left ventricular ejection fraction. Patients with HF with preserved ejection fraction, compared with other phenotypes, had a higher frequency of combinations with 3 main criteria in the composition. Patients with metabolic syndrome (MS) had a significantly higher risk of hospita­lization for cardiovascular causes (odds ratio 1,142, 95% confidence interval 1,033-1,263) than patients without MS (p=0,01). Among the identified MS clusters, cluster 1 was characterized by older patient age, a greater burden of kidney impairment/da­mage, and the poorest prognosis. Conclusion. A high prevalence of individual MS components was found among patients with heart failure. MS was diagnosed in 70,4% of cases. The broad profile of the obtained combinations of MS components reflects the diversity of me­tabolic disorders in HF patients. MS was associated with a significantly increased risk of hospitalization for cardiovascular causes compared to patients without MS. Cluster analysis demonstrated heterogeneity of patients with MS in clinical cha­racteristics and prognosis.

  • Open Access

    Role of Steroidal Mineralocorticoid Receptor Antagonists in the Treatment of Patients with Heart Failure with a Left Ventricular Ejection Fraction ≤40%. Expert council resolution

    by G. P. Arutyunov, A. S. Galyavich, S. N. Tereshchenko, F. T. Ageyev, O. L. Barbarash, S. V. Villevalde, I. V. Zhirov, N. A. Koziolova, Yu. M. Lopatin, S. V. Nedogoda, et al.

    Mineralocorticoid receptor antagonists are currently considered as a standard therapy for patients with heart failure with a reduced left ventricular ejection fraction. This drug group includes agents with different efficacy and safety profiles. The expert council’s resolution addresses the differentiated use of mineralocorticoid receptor antagonists in the treatment of patients with heart failure with a left ventricular ejection fraction ≤40%.

  • Open Access

    Chronic heart failure with improved ejection fraction. A review of the problem

    by Tatiana M. Uskach, Ускач Татьяна Марковна, Valeriia A. Amanatova, Аманатова Валерия Александровна, Ferzi S. Mamedov, Мамедов Ферзи Султанович, Sergey N. Tereshchenko, Терещенко Сергей Николаевич

    Chronic heart failure is a leading cause of increased mortality rates globally, including in the Russian Federation. Guideline-directed medical therapy plays a key role in the management of this patient cohort, particularly among individuals with reduced left ventricular ejection fraction. Of special interest is the subgroup with improved left ventricular ejection fraction, for which data remain limited and the issue of further medical treatment remains unresolved. This review aims to categorize this patient population and address the feasibility of discontinuing or reducing medical therapy.

  • Open Access

    Interleukin-1 activity regulators in acute decompensated heart failure: dependence on obesity degree

    by Alexandra A. Korotaeva, Elena V. Samoilova, Oleg S. Medvedev, Daria A. Drugova, Svetlana N. Nasonova, Igor V. Zhirov, Sergey N. Tereshchenko, Терещенко Сергей Николаевич

    Aim. To assess the circulating levels of IL-1 and its activity regulators, IL-1Ra and IL-1R2, in patients with acute decompensated heart failure (ADHF) depending on body mass index (BMI). Materials and methods. The study included 159 patients hospitalized for ADHF. Depending on the BMI, the patients were assigned to 5 groups. The first group included 30 patients with healthy weight (BMI25 kg/m2), the second – 50 overweight patients (25≤BMI30 kg/m2), the third – 38 patients with class I obesity (30≤BMI35 kg/m2), the fourth – 28 patients with class II obesity (35≤BMI40 kg/m2), the fifth group – 13 patients with class III obesity (BMI≥40 kg/m2). Results. With increasing BMI, IL-1 levels increased, while IL-1R2 levels, on the contrary, decreased, but no statistically significant differences were found. IL-1Ra concentrations changed ambiguously and had U-shaped dependence. IL-1Ra levels were lower in overweight patients than in normal weight and obese groups. At the same time, the increase in obesity was accompanied by higher IL-1Ra levels. The highest IL-1Ra value was observed at a BMI≥40 kg/m2. Conclusion. In ADHF an increase in obesity is accompanied by an increase in the inhibition of IL-1 activity, which may be one of the mechanisms by which adipose tissue exerts a protective effect.

  • Information value of QRS loop and ST-T interval planarity characteristics and applying deep learning to electrocardiogram analysis in amyloid cardiomyopathy

    by D. V. Drozdov, S. N. Nasonova, I. P Semchuk, E. D. Skaleukh, E. S. Li, O. Ya. Chaikovskaya, A. A. Shoshina, I. V. Zhirov, A. V. Samorodov, S. N. Tereshchenko

    Aim. To compare diagnostic effectiveness and interpretability of two following approaches to electrocardiogram analysis in amyloid cardiomyopathy (ACM): a deep learning model (1DResNet) and an algorithm for vectorcardiogram (VCG) loop planarity assessment.. Material and methods. The study was conducted on a dataset including electrocardiogram recordings from patients with verified ACM (n=99) and a control group (n=2673). Augmentation and undersampling were used to balance the classes. Two following methods were employed: a convolutional neural network (CNN) with the ResNet architecture and the Grad-CAM decision interpretation. QRS and ST-T segment planarity assessment (R2) was performed with random forest classification. R e sults . The 1D ResNet model demonstrated stable pathology detection with sensitivity and specificity of 75%. The Random Forest classifier, based on planarity characteristics, demonstrated higher performance as follows: specificity — 85%, predictive accuracy (precision) — 79%, sensitivity — 75%. Activation map analysis (Grad-CAM) revealed that the T-wave was the most significant signal area for the neural network in amyloid cardiomyopathy (93,75% contribution). This is consistent with the planarity method, where features of the repolarization segment also made the main contribution (57%) to the decision. Conclusion . Both methods confirm that key diagnostic abnormalities in amyloid cardiomyopathy are located in the repolarization phase (T-wave). The planarity based approach provides a physical interpretation (spatial heterogeneity), while Grad-CAM visualizes the diagnostic logic of the neural network, which coincides with pathophysiological assumptions.

  • Prospects for finerenone use in heart failure with a left ventricular ejection fraction ≥40%: value of the results of the FINEARTS-HF phase III randomized clinical trial (expert panel summary)

    by Yu. M. Lopatin, S. N. Tereshchenko, G. P. Arutyunov, S. V. Villevalde, A. S. Galyavich, D. V. Duplyakov, I. V. Zhirov, N. E. Zvartau, O. B. Irtyuga, N. A. Koziolova, et al.

    Heart failure with mildly reduced and preserved ejection fraction is a serious problem in modern healthcare due to its high prevalence, unfavorable prognosis, and significant limitations in optimal therapy. This article represents the re­solution of an expert panel devoted to the prospects for finerenone use in heart failure with a left ventricular ejection fraction ≥40%, based on the results of the FINEARTS-HF phase III randomized clinical trial. The data obtained demonstrate a high efficacy and safety profile for finerenone in this patient group, which rationales including this drug in widespread clinical practice for the treatment of sym­ptomatic heart failure with a left ventricular ejection fraction ≥40% after registration of the appropriate indication.

  • Treatment efficacy and adherence in patients with chronic heart failure according to the chronic heart failure registry in the Tyumen region

    by A.A. Airapetyan, E.M. Mezhonov, O.M. Reitblat, N.V. Lazareva, E.V. Sorokin, Yu.SH. Prints, I.V. Zhirov, S.N. Tereshchenko, S.A. Boytsov

    The objective of the study was to evaluate achievement of target doses of essential medications (ACE inhibitors/ARBs/ARNIs, beta-blockers, MRA and SGLT2) and patient adherence to therapy. We analyzed medication prescriptions depending on CHF phenotype and left ventricular ejection fraction (LVEF), as well as dynamics of clinical and laboratory parameters (LVEF and NT-proBNP). There was low rate of achievement of target doses for beta-blockers and ACE inhibitors/ARBs/ARNIs (<20% of patients), while MRAs were prescribed at optimal doses in more than 90% of cases. Only 50.6% of patients demonstrated high adherence to therapy. Repeated assessment of LVEF and NTproBNP was performed in only a subset of patients. However, patients on optimal medical therapy showed improvements of LVEF and decrease of NTproBNP. Therefore, it is necessary to increase physician awareness, improve compliance with clinical guidelines and intensify follow-up to improve treatment adherence and prognosis in patients with CHF.